Carter BloodCare

To: Carter BloodCare Customers
From: Hospital Relations Department
Date: January 14, 2020
Re: Circular of Information

Effective immediately, a modification to the Circular of Information regarding Babesia testing (in states where testing is required by the FDA) must be updated to reflect this practice. Additionally, information regarding bacterial testing for platelets (specifically at Carter BloodCare) has also been included.

In accordance with Food and Drug Administration (FDA) Guidance for Industry: An Acceptable Circular of Information for the Use of Human Blood and Blood Components, October 2017, can be found at the link below:
http://www.aabb.org/tm/coi/Documents/coi1017.pdf

Please note: The following information is to be considered a part of the Circular of Information as it applies to the General Information for Whole Blood and All Blood Components, Testing of Donor Blood section.

A licensed nucleic acid test (NAT) for Zika Virus RNA has been performed and found to be nonreactive.

A licensed NAT for Babesia has been performed and found to be nonreactive for blood collected in states where testing is required by FDA.

As a safety measure, Apheresis Platelets and pre-storage pools of whole blood derived platelets tested for bacteria using a primary culture method. As a safety measure, selected Apheresis Platelets are tested with a secondary rapid test for bacteria to extend product dating up to seven days.

Additionally, printed copies of the Circular of Information requested from Carter BloodCare will contain these statements.

CarterBloodCare ▪ Hospital Relations ▪ 2205 Highway 121 ▪ Bedford, Texas 76021
Veronica Moore, Director of Hospital Relations vmoore@carterbloodcare.org 817-412-5328
Andrea Sign, Manager of Client Relations asign@carterbloodcare.org 817-412-5825
Judy Thornburg, Hospital Relations Advocate jthornburg@carterbloodcare.org 817-412-5719